Document is current
Any future updates will be listed below
-
Authors
Klümper, Niklas https://orcid.org/0000-0002-3258-0586
Ralser, Damian J
Zarbl, Romina
Schlack, Katrin
Schrader, Andres Jan
Rehlinghaus, Marc
Hoffmann, Michèle J
Niegisch, Günter
Uhlig, Annemarie
Trojan, Lutz
Steinestel, Julie
Steinestel, Konrad
Wirtz, Ralph M
Sikic, Danijel
Eckstein, Markus https://orcid.org/0000-0001-5418-3349
Kristiansen, Glen
Toma, Marieta
Hölzel, Michael
Ritter, Manuel
Strieth, Sebastian
Ellinger, Jörg
Dietrich, Dimo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03369223 at ClinicalTrials.govDocuments that mention this clinical trial
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2021-002949
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
https://doi.org/10.1136/jitc-2019-000391
-
Funding
Funding for this research was provided by:
Gesellschaft für Urologie (KIN1/FE-19)
BONFOR Program of the Medical Faculty of the University of Bonn (2020-2A-12)
- License Information
